What changed
Deals & ownershipПротягом періоду з 9 по 16 листопада 2026 року керівники та директори Gilead Sciences, Inc. здійснили низку операцій з акціями та подали нові повідомлення про плани майбутніх продажів. Ці транзакції та наміри задокументовані у регуляторних звітах компанії.

Deals & ownershipOn October 15, 2026, two Gilead Sciences executives, Chief Financial Officer Andrew Dickinson and Chief Communications Officer Johanna Mercier, sold company shares. Each sold 3,000 shares at $156.22 per share, totaling approximately $468,660 for each transaction. Both operations were conducted under pre-approved trading plans, which set a specific sale schedule.

Upcoming events
As announced by the companies, read by code from their press releases, 8-Ks and official feeds; each date links its announcement. Companies can change dates. Dividends: common shares only; under T+1 settlement the ex-dividend date is normally the record date. Corporate calendar →
Company history
October 2026
GILEAD SCIENCES, INC.: 9 recorded developments from 9 official sources in 2026-10.
- 2026-09-15: Units to be sold: 3000; aggregate market value: 435870 USD; units outstanding: 1239955155 Source
- 2026-09-15: Units to be sold: 3000; aggregate market value: 432646.2 USD; units outstanding: 1239955155 Source
- 2026-09-16: Summary: S (open market or private sale): 1 transaction(s) on 2026-09-15, 3,000 disposed, total value 435,870 USD at a weighted average price of 145.29 USD; owned after the last one: 164,096 Source
- 2026-09-16: Summary: S (open market or private sale): 3 transaction(s) on 2026-09-15, 3,000 disposed, total value 432,646.24 USD at a weighted average price of 144.2154 USD; owned after the last one: 116,684 Source
- 2026-10-02: Summary: S (open market or private sale): 2 transaction(s) on 2026-10-01, 15,000 disposed, total value 2,218,507.5 USD at a weighted average price of 147.9005 USD; owned after the last one: 566,683 Source
- 2026-10-15: Units to be sold: 3000; aggregate market value: 468660 USD; units outstanding: 1239955155 Source
- 2026-10-15: Units to be sold: 3000; aggregate market value: 468660 USD; units outstanding: 1239955155 Source
- 2026-10-16: Summary: S (open market or private sale): 1 transaction(s) on 2026-10-15, 3,000 disposed, total value 468,660 USD at a weighted average price of 156.22 USD; owned after the last one: 161,096 Source
- 2026-10-16: Summary: S (open market or private sale): 1 transaction(s) on 2026-10-15, 3,000 disposed, total value 468,660 USD at a weighted average price of 156.22 USD; owned after the last one: 113,684 Source
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Changes in risk factors
The 10-Q filed October 30, 2026 compared with the 10-Q filed August 6, 2026: risk paragraphs that were added or dropped, quoted as filed. SEC
Added (29)
- | | (3) | | | — | | | (12) | | | — | | | (358) | | | — | | | (370)
- | | — | | | — | | | — | | | — | | | (1,029) | | | — | | | (1,029)
- Balance as of September 30, 2026 | | 1,241 | | | $ | 1 | | | $ | 9,841 | | | $ | 89 | | | $ | 3,107 | | | $ | (84) | | | $ | 12,955
Dropped (27)
- Balance as of March 31, 2026 | | 1,242 | | | $ | 1 | | | $ | 9,305 | | | $ | 78 | | | $ | 14,131 | | | $ | (84) | | | $ | 23,431
- | | (3) | | | — | | | (12) | | | — | | | (343) | | | — | | | (355)
- | | — | | | — | | | — | | | — | | | (1,031) | | | — | | | (1,031)
Found by comparing the two reports paragraph by paragraph, without AI. A new or dropped risk is not by itself a sign of trouble.
Insider trades
| Date | Person | Trade | Shares | Avg. price | Value | Filing |
|---|
| November 16, 2026 | Johanna Mercier | Sale 10b5-1 plan notice filed | 28,000 | $170.55 | $4,775,527 | SEC |
| November 16, 2026 | Andrew D Dickinson | Sale 10b5-1 plan notice filed | 3,000 | $171.47 | $514,410 | SEC |
| November 12, 2026 | Kelly A. Kramer | Sale 10b5-1 plan notice filed | 10,376 | $169.76 | $1,761,437 | SEC |
| November 6, 2026 | Wettan Keeley M Cain | Sale 10b5-1 plan notice filed | 3,399 | $164.11 | $557,810 | SEC |
| November 5, 2026 | Daniel Patrick O'Day | Sale 10b5-1 plan | 112,429 | $175.16 | $19,693,439 | SEC |
| November 4, 2026 | Daniel O'Day | Planned sale 10b5-1 plan | 112,429 | — | $18,828,485 | SEC |
| November 2, 2026 | Daniel Patrick O'Day | Sale 10b5-1 plan | 30,881 | $172.57 | $5,329,178 | SEC |
| October 30, 2026 | Daniel O'Day | Planned sale 10b5-1 plan | 45,881 | — | $7,598,352 | SEC |
| October 15, 2026 | Andrew D Dickinson | Sale 10b5-1 plan notice filed | 3,000 | $156.22 | $468,660 | SEC |
| October 15, 2026 | Johanna Mercier | Sale 10b5-1 plan notice filed | 3,000 | $156.22 | $468,660 | SEC |
All insider trades →
Large funds (13F)
| Fund | Shares | Value | Change in shares | Quarter |
|---|
| BlackRock | 125,246,865 | $18,668,045,217 | +2.8% | Q3 2026 |
| State Street | 60,954,967 | $9,085,337,831 | -0.4% | Q3 2026 |
| Fidelity (FMR) | 58,265,696 | $8,684,501,953 | -12.9% | Q3 2026 |
| Geode Capital Management | 30,190,640 | $4,485,711,723 | +0.4% | Q3 2026 |
| Capital Research Global Investors | 23,980,766 | $3,574,341,919 | +23.7% | Q3 2026 |
| Norges Bank (Norway's sovereign fund) | 21,965,555 | $2,775,128,219 | — | Q2 2026 |
| Wellington Management | 12,224,488 | $1,822,059,937 | -3.7% | Q3 2026 |
| Renaissance Technologies | 2,054,876 | $306,279,268 | -7.3% | Q3 2026 |
| D. E. Shaw & Co. | 1,909,369 | $284,591,449 | -16.8% | Q3 2026 |
| Citadel Advisors | 1,730,709 | $257,962,177 | -50.3% | Q3 2026 |
| Millennium Management | 1,628,685 | $242,755,499 | +11.6% | Q3 2026 |
| Two Sigma Investments | 517,066 | $77,068,687 | +26.4% | Q3 2026 |
| Bridgewater Associates | 321,419 | $47,907,502 | +10.5% | Q3 2026 |
| T. Rowe Price | 27,664,121 | $4,123,338 | -7.8% | Q3 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.